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Background: The estimated glomerular filtration rate (eGFR) is a well-known measure of kidney function and is
commonly used for the diagnosis and management of patients with chronic kidney disease. The inter-individual
variation in eGFR has significant genetic component. However, the identification of underlying genetic susceptibility
variants has been challenging. In an attempt to identify and characterize susceptibility genetic variant(s) we previously
identified the strongest evidence for linkage of eGFR occurring on chromosome 9q21 in the Mexican American
participants of San Antonio Family Heart Study (SAFHS). The objective of the present study was to examine whether
the common genetic variants in Neurotrophic Tyrosine Receptor Kinase 2 (NTRK2), a positional candidate gene on
9q21, contribute to variation in eGFR.
Results: Twelve tagging single nucleotide polymorphisms (SNPs) across the NTRK2 gene region were selected
(r2 ≥ 0.80, minor allele frequency of ≥ 0.05) from the Hapmap database. SNPs were genotyped by TaqMan assay
in the 848 Mexican American subjects participated in the SAFHS. Association analysis between the genotypes and
eGFR (estimated by the Modification of Diet in Renal Disease equation) were performed by measured genotype
approach as implemented in the program SOLAR. Of the 12 common genetic variants examined, the rs1036915
(located in 3′UTR) and rs1187274 (located in intron-14), present in perfect linkage disequilibrium, exhibited an
association (P = 0.017) with eGFR after accounting for the effects of age, sex, diabetes, diabetes duration, systolic
blood pressure and blood pressure medication. The carriers of minor allele of rs1036915 (G; 38%) had increased eGFR
(104 ± 25 ml/min/1.73 m2) in comparison to the carriers of major allele A (98 ± 25 ml/min/1.73 m2).
Conclusion: Together, our results suggest for the first time that the genetic variants in NTRK2 may regulate eGFR.
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Estimated glomerular filtration rate (eGFR) using serum
creatinine level is a validated measure of kidney function
although creatinine levels are known to be influenced by
diet and muscle metabolism. The eGFR is commonly
used to identify patients with chronic kidney disease
(CKD), a major risk factor for end stage kidney disease.
Several studies have reported a strong association be-
tween a mild change in eGFR and high risk of cardiovas-
cular death even after accounting for the influences of
traditional risk factors such as diabetes, hypertension,
and dyslipidemia [1]. Comparing individuals with stable
kidney function, both declining and increasing eGFR
were independently associated with a higher risk of car-
diovascular morbidity and mortality, posing a significant
financial burden to the health care systems [2]. Consid-
ering the significant health care costs problem associated
with CKD and cardiovascular disease, identifying add-
itional risk predictors influencing changes in eGFR over-
time is of paramount importance in public health.
Heritability estimate of eGFR demonstrated that 33%-
82% of the inter-individual variation in eGFR could be ex-
plained by additive genetic effects indicating that changes
in eGFR in a given individual is influenced by the genes
and their interaction with the environment [3]. Despite
intensive research, it has been challenging to identify
genetic determinants influencing the complex interplay
of inter-individual variation in eGFR. In an effort to
identify genes regulating eGFR, we previously performed
genome-wide linkage scan in Mexican American partici-
pants (N = 848) of the San Antonio Family Heart Study
(SAFHS) and identified the strongest evidence for
linkage of eGFR to occur on chromosome 9q21 near
the markers D9S301-D9S922 with a LOD score of 3.9
(P = 0.00005) [4].
One of the positional candidate genes located within
the critical linkage interval is the Neurotrophic Tyrosine
Receptor Kinase 2 (NTRK2) also known as the Tyrosine
receptor kinase B (TRKB)/Tropomycin-related kinase B
(TrkB). NTRK2 belongs to the family of NTRK proteins
and is the membrane-bound receptor for the Neurotro-
phin (NT)-4/5 and Brain-Derived Neurotrophic Factor
(BDNF). BDNF binding causes tyrosine phosphorylations
in the intracellular domains of NTRK2 which in turn
triggers the signaling cascades of mitogen-activated
protein kinase (MAPK), phospholipase Cγ (PLCγ), and
phosphatidylinositol 3-kinase (PI3K) pathways [5]. Thus,
BDNF regulates the development, survival, and differenti-
ation of neurons through binding with NTRK2 [6]. In
addition, BDNF/NTRK2 signaling plays a role in human
kidney development especially in tubulogenesis and juxta-
glomerular apparatus [7,8].
Besides the developmental role, BDNF/NTRK2 signal-
ing appears to be an important downstream target ofMelanocortin 4 receptor mediated regulation of food
intake and energy expenditure in the hypothalamus [9].
BDNF/NTRK2 signaling increases fat oxidation in skel-
etal muscle through activation of AMP-activated protein
kinase [10]. Furthermore, BDNF/NTRK2 deficiency was
associated with increased weight in mice and humans
[9,11]. Mutations in NTRK2 have been associated with
obesity and eating disorder in man [12-14].
Given the functional significance of NTRK2 and its
localization on chromosome 9q21, a genetic region linked
with eGFR, the objective of the present study is to deter-
mine whether the common genetic variants in NTRK2
are associated with eGFR in the Mexican American par-
ticipants of SAFHS.
Methods
Subjects and phenotypic data
The recruitment of the San Antonio Family Heart Study
(SAFHS) family member and data collection procedures
from more than 40 extended families have been described
previously [15]. Briefly, the cohort was randomly selected
from the community with the requirements that they are
of Mexican-American ancestry regardless of preexisting
medical conditions, part of a large family, and live within
the San Antonio region. Blood samples were collected
from all participants after an overnight fast and plasma
and serum were prepared and stored at −80°C until ana-
lyzed. The metabolic, hemodynamic, anthropometric, and
demographic variables were collected for all the partici-
pants. Diabetes was diagnosed if the 2 h glucose level was
11.1 mmol/l or higher, or if the subject had been pre-
scribed antidiabetic medication. Although a total of 1400
subjects were recruited for SAFHS from 40 large families,
kidney-related phenotypic data were collected for only
848 participants from 21 families, who came to the clinic
during their 3rd visit. Therefore, this study involves the
848 subjects from 21 families for whom genotypic and
phenotypic data are available. GFR was estimated as
described previously [4] using the four variables Modifi-
cation of Diet in Renal Disease (MDRD) formula [16]:
eGFR (ml/min per 1.73 m2) = 186 × [plasma creatin-
ine (mg/dl)] × (age)− 0.203 × (0.742, if female) × (1.210, if
African American). Estimation of albumin to creatinine
ratio (ACR) has previously been described [4]. The quan-
titative trait values were inverse-normalized and used in
the association analyses since their raw data were non-
normally distributed. The Institutional Review Board of
the University of Texas Health Science Center at San
Antonio approved all procedures, and all subjects gave
informed consent.
SNP selection and genotyping
To identify common genetic variations in NTRK2 gene,
tagging SNPs were downloaded from the Hapmap
Table 1 Clinical characteristics of the genotyped SAFHS
participants (N = 848)
Variables Mean ± SD or %
Females 63
Type 2 diabetes 21.6
Age (yrs) 47.9 ± 14.8
Systolic blood pressure (mm Hg) 124.4 ± 19.0
Diastolic blood pressure (mm Hg) 69.8 ± 23.0
Body mass index (kg/m2) 31.8 ± 7.2
Total Cholesterol (mg/dl) 180.6 ± 38.5
High density lipoprotein-Cholesterol (mg/dl) 48.2 ± 13.6
Triglycerides (mg/dl) 129.2 ± 86.6
Albumin to Creatinine Ratio 0.060 ± 0.4
Estimated Glomerular Filtration Rate (ml/min/1.73 m2) 99.2 ± 25.7
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morphisms (SNPs) was performed with the tagger pro-
gram implemented in Haploview (Ver 3.2). Haploview
was used to assess linkage disequilibrium for all possible
SNP pairs by determining r2. Twelve tagging SNPs were
selected based on the pair-wise tagging (r2 0.80, MAF
0.05) using genotype data from the unrelated Hapmap
CEU individuals. All the 12 SNPs were genotyped in the
study participants (N = 848) by TaqMan assay (Applied
Biosystems, CA, USA). Allelic discrimination PCR was
carried out on a GeneAmp PCR system 9700 (Applied
Biosystems), and fluorescent signals were detected on an
ABI PRISM 7700 sequence detector (Applied Biosystems).
To assure accuracy of the genotyping, coded blind repli-
cate samples (10%) were included in each assay. Genotypic
data with 0% of genotyping error and 0% of inheritance
error were subjected to statistical association analyses.Statistical association analysis
SNP genotypes were checked for Mendelian consistency
using the program SimWalk2 [17]. Allele frequencies
were estimated using maximum likelihood estimation
methods, which account for the pedigree structure. The
estimates of the allele frequencies and their standard
errors were obtained using the software package, Se-
quential Oligogenic Linkage Analysis Routines (SOLAR)
[18]. Estimates of linkage disequilibrium (LD) between
SNPs were determined by calculating pair-wise D’ and r2
statistics. Population stratification was tested by the
quantitative transmission disequilibrium test (QTDT) as
implemented in SOLAR. To investigate the association
between NTRK2 SNPs and eGFR-related traits, the mea-
sured genotype analysis (MGA) implemented in SOLAR
was employed. This approach extends the classical vari-
ance component-based biometrical model to account for
both the random effects of kinship and the main effects
of SNP genotypes [19]. A p value ≤ 0.05 was considered
to be significant. Based on the number of participants
(N = 848), there is 83% power to detect an association at
the nominal (0.05) level of significance that accounts for
as little as 1% of the phenotypic variation.Results
Table 1 shows the clinical characteristics of the geno-
typed individuals. Of the participants, 63% of them were
females and the mean age of the study subjects was 48.
Among the participants, 22% of them had type 2 dia-
betes (T2DM). Also, there were about 6% of the partici-
pants had eGFR lesser than 60 ml/min/1.73 m2.
Tagging SNPs selected for genotyping in SAFHS
participants are shown in Figure 1. Genotypic data of
all SNPs tested in our population were consistent
with the Hardy-Weinberg Equilibrium expectations. Theallele frequencies of the SNPs are shown in Table 2. To
identify the hidden population stratification, we per-
formed QTDT that permits a formal test of likely popula-
tion heterogeneity on a marker-specific basis. Using this
test, we found no evidence for such stratification. Further-
more, the QTDT results were consistent with the more
powerful measured genotype analyses. Before perform-
ing statistical association analysis, we estimated the
pairwise LD (r2) between all the 12 SNPs and found
that the pairwise LD ranged from 0 to 1.0. As can be
seen from Figure 1, the high pairwise LD was found
for the following SNPs pairs: rs1187274-rs1036915 (r2 =
1.0). The rs1187274 and rs1036915 SNPs are located
18 kb away from each other and are in last intron-14 and
3′UTR respectively.
We performed the association analysis between geno-
types and eGFR using measure genotype analysis as im-
plemented in program SOLAR. Table 2 shows the allele
frequencies of the SNPs examined and their association
with eGFR. Of the 12 SNPs examined for association,
the 3′UTR variant rs1036915 (A/G) with minor allele
(G) frequency of 38%, exhibited evidence of suggestive
association with eGFR (P = 0.017) after accounting for the
potential covariate effects of the age, sex, diabetes, dia-
betes duration, systolic blood pressure (SBP), blood pres-
sure medication. The rs1187274 which was in complete
LD (r2 = 1; Figure 1) with rs1036915 also exhibited a
similar association with eGFR. We also performed the
association testing using diastolic blood pressure as an
additional covariate in our original model and found
that the rs1036915 (P = 0.038) and rs1187274 (P = 0.021)
were still suggestively associated with eGFR. Since our
eGFR linkage region on 9q21 was also linked with serum
creatinine (SrCr) in Mexican Americans [4], we extended
our investigation whether the NTRK2 SNPs examined are
also associated with SrCr. Interestingly, the two SNPs that
showed an association with eGFR were also found to be
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Figure 1 Linkage disequilibrium (LD) between polymorphisms within the NTRK2 gene. Polymorphisms are labeled on the y-axis. Pairwise
LD is estimated using r2 values and depicted in the figure by the color intensity of the shaded box. The diagonal represents a comparison of each
polymorphism against itself (i.e., r2 = 1.0).
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rs1187274 (P = 0.040)] after adjusting for the effects of
age, sex, diabetes, diabetes duration, systolic blood pres-
sure, and blood pressure medication (Table 2). In addition,
we also examined whether NTRK2 SNPs are associated
with other measure of GFR estimated by the Cockcraft-
Gault (GC) formula [20], also known as creatinine clear-
ance (CrCl). However, our analysis failed to find an associ-
ation between the NTRK2 SNPs and eGFR (estimated by
GC equation) after adjusting for effects of age, sex, dia-
betes, diabetes duration, systolic blood pressure, and blood
pressure medication (data not shown).Discussion
Heritability of eGFR, which is a measure of how much of
the eGFR variability can be attributed to genetic causes
and is calculated by observation of phenotypic correla-
tions between relatives in families, is estimated to range
from 33% to 82% [3]. Such a vast difference in heritability
estimates depends on a number of factors that includes
heterogeneous study population, sample size, pedigree
structures, ascertainment criteria, treatment effects, defi-
nitions of kidney function, diabetes duration, hypertension
status, and covariates used to estimate the heritability. For
example, Bochud et al. [21], reported a high heritability of
Table 2 Association analysis between the NTRK2 polymorphisms and eGFR and SrCr
SNPs SNP ID Location
on NTRK2
Chromosome
position (GRCh37/hg19)
Major / Minor allele (%)
in Europeans (HapMap)
Major / Minor allele (%)
in Mexican Americans
eGFR
(P values)*
Serum creatinine
(SrCr) (P values)*
1 rs11140800 3′UTR 87508137 A(52) / C (48) A(52) / C (48) 0.184 0.163
2 rs995861 3′UTR 87541642 T (67) / C (33) T (69) / C (31) 0.298 0.375
3 rs1036915 3′UTR 87437849 A (64) / G (36) A (62) / G (38) 0.017 0.040
4 rs1187274 Intron-14 87419789 G (58) / C (42) G (60) / C (40) 0.017 0.038
5 rs1187350 Intron-4 87295237 A (55) / G (45) A (60) / G (40) 0.408 0.598
6 rs1187352 Intron-4 87293457 C (64) / T (36) C (78) / T (22) 0.975 0.888
7 rs1867283 3′UTR 87450766 A (51) / G (49) A (53) / G (47) 0.679 0.521
8 rs2083828 3′UTR 87447045 C (52) / A (48) C (56) / A (44) 0.126 0.128
9 rs2808707 3′UTR 87558294 G (58) / T (42) G (54) / T (46) 0.079 0.076
10 rs7019555 3′UTR 87614445 A (71) / G (29) A (76) / G (24) 0.255 0.551
11 rs10746747 Intron-11 87354637 T (70) / A (30) T (66) / A (34) 0.960 0.965
12 rs10780690 3′UTR 87478172 G (52) / T (48) G (54) / T (46) 0.966 0.792
*eGFR (estimated Glomerular filtration rate by MDRD equation) and SrCr (serum creatinine) were adjusted for the effects of age, sex, diabetes, diabetes duration,
systolic blood pressure, blood pressure medication.
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subjects from 66 pedigrees) each containing at least
two hypertensive members. GFR was estimated using
Cockcroft-Gault formula. Age and sex were used as co-
variates in the heritability estimate. We recently reported
a heritability of eGFR of 21% in Mexican American fam-
ilies (848 subjects from 26 pedigrees) participated for the
SAFHS [4]. SAFHS participants were selected randomly
from a census tract in San Antonio of low-income
Mexican Americans regardless of any preexisting med-
ical conditions. GFR was estimated by MDRD equation.
Heritability was estimated accounting age, sex, BMI,
blood pressure medication and diabetic duration as
covariates in SAFHS participants. While, the population
heterogeneity continues to be a major problem, plus as
many factors that may have different genetic regulation
influencing eGFR variability, the heritability estimates
thus clearly indicate that additive genetic effects have
significant influence on the inter-individual variation in
eGFR. Family-based genome-wide linkage and associ-
ation scans are being employed to identify genetic
regions where multiple susceptibility genes/genetic vari-
ants may aggregate and explain a larger proportion of
the heritability of eGFR [4,22-33]. Despite intense re-
search in localization of genes, only a few genes have
been associated with eGFR. The susceptibility gene
with major effect on eGFR is yet to be identified. In
an effort to identify gene(s) regulating eGFR, we previ-
ously reported the localization of a genetic region on
chromosome 9q21 linked with eGFR in the Mexican
participants of SAFHS [4].
The 1-LOD support interval around the linkage signal
on 9q21 spans about 15 MB (D9S301-D9S1120). A search
of current genome databases indicate that there areseveral expressed sequence tagged sites (ESTs) and
approximately 40 genes of known function that have
been mapped to this region (https://genome.ucsc.edu).
Although none of the known positional genes have been
reported to have a direct functional relevance to kidney
function, NTRK2 was selected to screen for SNPs in the
present study based on its association with obesity. How-
ever, genetic variants in another positional candidate
gene, FERM domain containing 3 (FRMD3), have been
recently reported to be associated with eGFR [32] and
diabetic nephropathy (DN) [34]. Although the functional
significance of the association of FRMD3 with DN is not
clearly known, the promoter variant associated with DN
may influence nephropathy through generating the ne-
cessary binding site for the proteins involved in the bone
morphogenetic protein signaling pathways [35].
In the present study, we scanned the positional candi-
date gene NTRK2 for genetic variants to identify whether
the common genetic variants in NTRK2 selected from
the HapMap database have any functional relevance to
eGFR linkage. Although the HapMap genome browser
release #27 merging genotypes and frequencies of “phase
1, 2 and 3” datasets indicates the presence of 39 tagging
SNPs in NTRK2 in unrelated European Caucasians, the
12 tagging SNPs selected and genotyped for the present
study were based on the HapMap genome browser re-
lease #24; phase 1 in 2008. Furthermore, the LD pattern
that we observed in our Mexican American participants
(rs1187274-rs1036915; r2 = 1.0) was not the same as
reported in Europeans, Chinese, Yorubans and Japanese
individuals (HapMap release #24; phase 1). Of the 12
common genetic variants selected from the HapMap data-
base and examined for association, the SNP rs1036915
that was in perfect LD with rs1187274 showed a
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0.017) after accounting for the effects of confounding fac-
tors (Table 2). We tested the mean eGFR values for
rs1036915. The carriers of minor allele (G; 38%) had
increased eGFR (104 ± 25 ml/min/1.73 m2) in comparison
to the carriers of major allele A (98 ± 25). Although the
functional significance of the association of rs1036915
with eGFR needs to be elucidated, the genetic variants
located about 1.5 Mb upstream of rs1036915 have been
reported to be associated with eGFR [32] and diabetic
nephropathy [34]. Therefore, a thorough high density SNP
mapping in and around of the NTRK2 may identify func-
tional variants that could potentially relate to the GFR
linkage finding.
Despite several strengths, our results should be inter-
preted with caution. Once the issue of multiple testing is
accounted, the association observed for rs1036915/
rs1187274 with eGFR becomes insignificant. GFR esti-
mated by MDRD equation is not validated in our Mexican
American cohorts. However, the GFR estimated using
MDRD formula is the best validated method for convert-
ing serum creatinine values into eGFR [36] and being used
in several linkage studies [22-33]. Although the eGFR
levels seem to be normal in our study participants
(Table 1), this study was designed to identify the genetic
variants influencing variation in eGFR (high or low filtra-
tion) in Mexican Americans participants. Also, there were
about 6% of participants had eGFR lesser than 60 ml/min/
1.73 m2.
Conclusion
In conclusion, we provide evidence for the first time that
common genetic variants of NTRK2 are associated with
variation in eGFR although the magnitude of the genetic
effects appears to be relatively small. However, the asso-
ciation results presented in this study may be useful for
the future meta-analysis validating these SNPs. High
density SNP mapping of the critical linkage interval on
9q21 will eventually help to identify the genetic suscepti-
bility variants for eGFR. Identification of susceptibility
variants/genes will open a new avenue to elucidate the
functional mechanisms by which the variants/genes
contribute to renal dysfunction and could eventually
help facilitate prediction, development of improved
treatment, and prevention of changes in GFR, a strong
risk factor for progression of CKD/ESRD as well as asso-
ciated cardiovascular morbidity and mortality.
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